Latest news - Page 6 of 8 - Explicyte Immuno-Oncology

By charles_lbs20 April 20214 June 2024

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE)

Read our latest paper, titled Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.

automated histopathology IHC service tumor slides services

By charles_lbs25 February 20213 June 2024

Explicyte and Institut Bergonié associate in a clinical trial report publication

To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran a multiplexed immunohistofluorescence panel, in addition to Dapi.

By charles_lbs10 December 20203 June 2024

Explicyte is proud to be a certified Nanostring partner…Let’s start the Digital Spatial Profiling revolution together!

It becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), the Digital Spatial Profiling revolution has started.

Data analysis immuno-oncology biomarkers CRO services bioinformatics

By charles_lbs8 October 20203 June 2024

Quantitative histology to feature the tumor immune contexture

To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis.

By charles_lbs18 June 20204 June 2024

AACR Virtual Annual Meeting 2020… Discover our collaborative poster with Domain Therapeutics

Explicyte will be attending the AACR Virtual Annual Meeting 2020 and will present new results from its collaborative work with Domain Therapeutics on the GPCRome modulation in the context of cancer immunotherapy.

By charles_lbs18 June 20204 June 2024

Anti-angiogenic therapy combination with hypoxia-regulating agent leads to improved tumor regression

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

By charles_lbs18 June 20204 June 2024

Deciphering anti-PDL1 effect in a syngeneic mouse model of sarcoma

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

cytokine release assay CRO immuno-oncology

By charles_lbs16 April 20203 June 2024

Cytokine release as a relevant surrogate for the immune cell subset function assessment on an in vitro platform of IO

Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.

By charles_lbs5 March 20204 June 2024

IDO targeting in sarcoma: biological and clinical implications

New explicyte publication in Frontiers in Immunology!

digital pathology service tumor slides staining acquisition company

By charles_lbs20 February 20203 June 2024

B cells as key players in shaping anti-tumor immune response

B cells are to the forefront of cancer immunotherapy. Discover how!

Take Part Of The Next Anti-CTLA4 Explicyte Shuttle

By charles_lbs29 January 20204 June 2024

New in vivo shuttle session: syngeneic mouse tumor models for novel drug assessment and MoA deciphering

How about an opportunity to assess your compounds in a comprehensive and cost-effective manner? Explicyte is planning a new in vivo shuttle session by mid March, to be held on a series of either subcutaneously- or orthotopically-inoculated syngeneic tumor mouse models.

By charles_lbs3 December 20193 June 2024

Explicyte will be attending the ESMO Immuno-Oncology Congress In Geneva

We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We are glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.

Previous page 1 … 4 5 6 7 8 Next page